<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393702</url>
  </required_header>
  <id_info>
    <org_study_id>10.11</org_study_id>
    <nct_id>NCT03393702</nct_id>
  </id_info>
  <brief_title>Pain Control in Children and Adolescent After Thoracic Surgery: The Effect of Gabapentin</brief_title>
  <official_title>Efficacy of Gabapentin as Adjuvant for Postoperative Pain in Pediatric Thoracic Surgery - a Randomized Triple Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute for Tuberculosis and Lung Diseases, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute for Tuberculosis and Lung Diseases, Poland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is performed in patients aged 5-18 years after thoracic surgery. The primary aim of
      this study is to determine whether the use of gabapentin will improve postoperative
      multimodal analgesia and reduce consumption of ropivacaine with fentanyl or morphine in
      children and adolescent after the Ravitch procedure and thoracotomy. Secondary aims are to
      evaluate whether use of gabapentin reduces pain and anxiety scores, decreases postoperative
      nausea and vomiting, and improves patient satisfaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects are randomized to the Gabapentin or Placebo group. All patients receive
      preoperative gabapentin (15 mg/kg, treatment) or placebo, respectively and after surgery
      either gabapentin (7,5 mg/kg, treatment) or placebo 2 times per day for 3 days, respectively.

      Patients are subjected to the same anaesthesia protocol. Postoperative analgesia are achieved
      with either continuous ropivacaine 0.2%/fentanyl 5.0 μg/ml infusion through a thoracic
      epidural catheter (N=40; Gabapentin n=20, Placebo n=20), or intravenous infusion of morphine
      (N=40; Gabapentin n=20, Placebo n=20). All patients receive acetaminophen and non-steroidal
      anti-inflammatory drugs, and metamizol as a &quot;rescue drug&quot;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total ropivacaine/fentanyl consumption.</measure>
    <time_frame>postoperative day: 0-3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total morphine consumption.</measure>
    <time_frame>postoperative day: 0-3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity scores at rest (FLACC for patients &lt;7 y.o., NRS for patients &gt;7 y.o.)</measure>
    <time_frame>postoperative day: 0-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity scores during deep breathing (FLACC for patients &lt;7 y.o., NRS for patients &gt;7 y.o.)</measure>
    <time_frame>postoperative day: 0-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity scores during coughing (FLACC for patients &lt;7 y.o., NRS for patients &gt;7 y.o.)</measure>
    <time_frame>postoperative day: 0-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety intensity scores.</measure>
    <time_frame>before surgery, postoperative day 3</time_frame>
    <description>Patients rate their anxiety using State-Trait Anxiety Inventory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Occurrence</measure>
    <time_frame>first 3 days after surgery</time_frame>
    <description>Incidence and severity of nausea, vomiting, pruritis, sedation, dizziness, urinary retention, complication in relation to administering of the drugs to epidural space.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of doses of metamizol as a &quot;rescue drug&quot;</measure>
    <time_frame>postoperative day: 0-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction.</measure>
    <time_frame>first 3 days after surgery</time_frame>
    <description>Responses can range from 0 (very dissatisfied) to 10 (very satisfied).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Surgery, Thoracic</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose preoperative gabapentin.
After surgery gabapentin 2 times per day for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose preoperative placebo control.
After surgery placebo 2 times per day for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Patients in this arm of the study receive identical capsules, containing 15 mg/kg of oral gabapentin.
Patients after surgery receive identical capsules, containing 7,5 mg/kg of oral gabapentin 2 times per day.</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Gabapentin TEVA, capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in this arm of the study receive identical placebo capsules 1 hour before surgery.
Patients after surgery receive identical placebo capsules 2 times per day.</description>
    <arm_group_label>Placebo Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  5 - 18 years of age;

          -  surgery: lateral thoracotomy or Ravitch procedure;

          -  ASA 1-3;

          -  postoperative analgesia: thoracic epidural analgesia or intravenous infusion of
             morphine.

        Exclusion Criteria:

          -  allergy or sensitivity to gabapentin;

          -  history of chronic pain or daily analgesic use;

          -  diagnosed with psychiatric disorders;

          -  treated oncologically;

          -  with impaired verbal communication;

          -  the lack of postoperative chest drainage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucyna Tomaszek, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute for Tuberculosis and Lung Diseases, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucyna Tomaszek, PhD</last_name>
    <phone>4818 267 60 60</phone>
    <phone_ext>243</phone_ext>
    <email>ltomaszek@igrabka.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucyna Tomaszek, PhD</last_name>
    <phone>48182676060</phone>
    <phone_ext>243</phone_ext>
    <email>ltomaszek@igrabka.edu.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute for Tuberculosis and Lung Diseases, Pediatric Division</name>
      <address>
        <city>Rabka-Zdrój</city>
        <state>Małopolska</state>
        <zip>34-700</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucyna Tomaszek, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Dariusz Fenikowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piotr Maciejewski, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Rusy LM, Hainsworth KR, Nelson TJ, Czarnecki ML, Tassone JC, Thometz JG, Lyon RM, Berens RJ, Weisman SJ. Gabapentin use in pediatric spinal fusion patients: a randomized, double-blind, controlled trial. Anesth Analg. 2010 May 1;110(5):1393-8. doi: 10.1213/ANE.0b013e3181d41dc2.</citation>
    <PMID>20418301</PMID>
  </reference>
  <reference>
    <citation>Mayell A, Srinivasan I, Campbell F, Peliowski A. Analgesic effects of gabapentin after scoliosis surgery in children: a randomized controlled trial. Paediatr Anaesth. 2014 Dec;24(12):1239-44. doi: 10.1111/pan.12524. Epub 2014 Sep 17.</citation>
    <PMID>25230144</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute for Tuberculosis and Lung Diseases, Poland</investigator_affiliation>
    <investigator_full_name>Lucyna Tomaszek, PhD, RN</investigator_full_name>
    <investigator_title>Director of Nursing, Specialist Nurse in Anesthesia and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>Postoperative pain</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Postoperative Complications</keyword>
  <keyword>Patient Satisfaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

